Zidebactam/cefepime - Wockhardt

Drug Profile

Zidebactam/cefepime - Wockhardt

Alternative Names: WCK-5222; Zidebactam/cefepime intravenous - Wockhardt

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Wockhardt
  • Developer Quintiles; Wockhardt
  • Class Antibacterials; Azabicyclo compounds; Cephalosporins; Piperidines; Small molecules; Sulfoxides
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gram-negative infections

Most Recent Events

  • 26 Oct 2016 Preclinical data from in vitro studies presented at the IDWeek 2016
  • 01 Oct 2016 Wockhardt initiates a phase I pharmacokinetics trial in subjects with Renal impairment in USA (NCT02942810)
  • 01 Apr 2016 Wockhardt in collaboration with Quintiles completes a phase I trial in Gram-negative infections (In volunteers) in USA (NCT02707107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top